원문정보
초록
영어
This study was carried out to evaluate neutralization effect of a new fusion protein of VP19 and VP28 as a vaccine. The recombinant fusion protein, rVP19-28 was obtained from a bacterial expression system, E. coli BL21/pET28a. The polyclonal antisera against rVP19-28 were produced using white rabbit. The dilutions of WSSV stock ranged from 1×101 to 1×106 were used to determine 90-100% mortility in P enaeus vannamei by intramuscular injection. A 104 diluted stock of WSSV was mixed with various antiserum concentrations and injected to shrimp. At 12 days of post challenge, the shrimp in the positive control with WSSV showed 100% mortality. The shrimp with pre-immune serum resulted in 83% mortality at 14 days of post challenge. The WSSV
was pre-incubated with 0.05 ml, 0.5 ml and 5 ml of rVP19-28 antisera showed 71%, 56% and 38% mortalities, respectively at 21 days of post challenge. These results indicated that the recombinant fusion antigens can be used as a potential vaccine to protect shrimp from WSSV infection.